Related references
Note: Only part of the references are listed.Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway
Qian Wu et al.
ACTA PHARMACOLOGICA SINICA (2021)
The anti-STAT1 polyphenol myricetin inhibits M1 microglia activation and counteracts neuronal death
Diana Boriero et al.
FEBS JOURNAL (2021)
Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas
Devin Dersh et al.
IMMUNITY (2021)
Myricetin: A review of the most recent research
Xiaominting Song et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Advance investigation on synthetic small-molecule inhibitors targeting PD-1/PD-L1 signaling pathway
Annoor Awadasseid et al.
LIFE SCIENCES (2021)
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
Kai Tang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer
Chunfeng Xie et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer
Yufan Qiu et al.
ONCOGENE (2021)
Regulation of CD47 expression by interferon-gamma in cancer cells
Zi-Han Ye et al.
TRANSLATIONAL ONCOLOGY (2021)
Extracellular and nuclear PD-L1 in modulating cancer immunotherapy
Wenjun Xiong et al.
TRENDS IN CANCER (2021)
Tumor organoid-T-cell coculture systems
Chiara M. Cattaneo et al.
NATURE PROTOCOLS (2020)
Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5
Yang Liu et al.
ACTA PHARMACEUTICA SINICA B (2020)
Carnosine to Combat Novel Coronavirus (nCoV): Molecular Docking and Modeling to Cocrystallized Host Angiotensin-Converting Enzyme 2 (ACE2) and Viral Spike Protein
Loai M. Saadah et al.
MOLECULES (2020)
A study on the mechanism of bruceine D in the treatment of non-small cell lung cancer H1299 cells
Xiao-Yun Shen et al.
WORLD JOURNAL OF TRADITIONAL CHINESE MEDICINE (2020)
Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer
Min Luo et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications
Yasaman Taheri et al.
BMC COMPLEMENTARY MEDICINE AND THERAPIES (2020)
Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy
Samantha M. Morrissey et al.
TRENDS IN CANCER (2020)
Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity
Elise Alspach et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2019)
Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours
Valentina Martin et al.
BRITISH JOURNAL OF CANCER (2019)
Tryptophan-kynurenine pathway attenuates β-catenin-dependent pro-parasitic role of STING-TICAM2-IRF3-IDO1 signalosome in Toxoplasma gondii infection
Tanmay Majumdar et al.
CELL DEATH & DISEASE (2019)
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Mauro Poggio et al.
CELL (2019)
Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma
Rui-Yan Wu et al.
CLINICAL CANCER RESEARCH (2019)
FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway
Piao Li et al.
JOURNAL OF IMMUNOLOGY (2019)
PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy
Xinyi Tu et al.
MOLECULAR CELL (2019)
Myricetin Suppresses the Propagation of Hepatocellular Carcinoma via Down-Regulating Expression of YAP
Minjing Li et al.
CELLS (2019)
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures
Carminia Maria Della Corte et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Mechanisms regulating PD-L1 expression on tumor and immune cells
Shuming Chen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Anti-tumor effects and associated molecular mechanisms of myricetin
Min Jiang et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Chemopreventive effect of Myricetin, a natural occurring compound, on colonic chronic inflammation and inflammation-driven tumorigenesis in mice
Mei-Jia Zhang et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
IDO1 in cancer: a Gemini of immune checkpoints
Lijie Zhai et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
Ioannis Zerdes et al.
ONCOGENE (2018)
Myricetin suppresses breast cancer metastasis through down-regulating the activity of matrix metalloproteinase (MMP)-2/9
Yingqian Ci et al.
PHYTOTHERAPY RESEARCH (2018)
The Natural Compound Myricetin Effectively Represses the Malignant Progression of Prostate Cancer by Inhibiting PIM1 and Disrupting the PIM1/CXCR4 Interaction
Chen Ye et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen et al.
NATURE (2018)
Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
Takefumi Komiya et al.
FRONTIERS IN ONCOLOGY (2018)
Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'
George C. Prendergast et al.
TRENDS IN CANCER (2018)
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Marian L. Burr et al.
NATURE (2017)
Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation
Marek Wieczorek et al.
FRONTIERS IN IMMUNOLOGY (2017)
Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells
Melanie R. Power Coombs et al.
CANCER LETTERS (2016)
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2016)
Myricetin induces apoptosis via endoplasmic reticulum stress and DNA double-strand breaks in human ovarian cancer cells
Ye Xu et al.
MOLECULAR MEDICINE REPORTS (2016)
In vitro and in vivo evaluation of functionalized chitosan-Pluronic micelles loaded with myricetin on glioblastoma cancer
Gang Wang et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2016)
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Vassiliki A. Boussiotis
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Myricetin: A Dietary Molecule with Diverse Biological Activities
Deepak Kumar Semwal et al.
NUTRIENTS (2016)
Chemoprevention of intestinal tumorigenesis by the natural dietary flavonoid myricetin in APCMin mice
Ye Li et al.
ONCOTARGET (2016)
Screening and biological evaluation of myricetin as a multiple target inhibitor insulin, epidermal growth factor, and androgen receptor; in silico and in vitro
Pushpendra Singh et al.
INVESTIGATIONAL NEW DRUGS (2015)
Myricetin inhibits proliferation and induces apoptosis and cell cycle arrest in gastric cancer cells
Jianfang Feng et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2015)
Adaptive Immune Resistance: How Cancer Protects from Immune Attack
Antoni Ribas
CANCER DISCOVERY (2015)
Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
Ivan Theate et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Development of a myricetin/hydroxypropyl-β-cyclodextrin inclusion complex: Preparation, characterization, and evaluation
Yashu Yao et al.
CARBOHYDRATE POLYMERS (2014)
Enhancement of recombinant myricetin on the radiosensitivity of lung cancer A549 and H1299 cells
Shijie Zhang et al.
DIAGNOSTIC PATHOLOGY (2014)
Efficient conversion of myricetin from Ampelopsis grossedentata extracts and its purification by MIP-SPE
Shian Zhong et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2014)
Kynurenines in CNS disease: regulation by inflammatory cytokines
Brian M. Campbell et al.
FRONTIERS IN NEUROSCIENCE (2014)
Inhibitory effects of myricetin on mammalian DNA polymerase, topoisomerase and human cancer cell proliferation
Kazuaki Shiomi et al.
FOOD CHEMISTRY (2013)
HIV-1 Nef and T-cell activation: a history of contradictions
Tristan J. Markle et al.
FUTURE VIROLOGY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Myricetin induces pancreatic cancer cell death via the induction of apoptosis and inhibition of the phosphatidylinositol 3-kinase (PI3K) signaling pathway
P. A. Phillips et al.
CANCER LETTERS (2011)
The Two Faces of Interferon-γ in Cancer
M. Raza Zaidi et al.
CLINICAL CANCER RESEARCH (2011)
NLR family member NLRC5 is a transcriptional regulator of MHC class I genes
Torsten B. Meissner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Myricetin directly targets JAK1 to inhibit cell transformation
Takuma Kumamoto et al.
CANCER LETTERS (2009)
Targeting STAT1 by myricetin and delphinidin provides efficient protection of the heart from ischemia/reperfusion-induced injury
Tiziano M. Scarabelli et al.
FEBS LETTERS (2009)
Molecular Mechanisms of IFN-gamma to Up-Regulate MHC Class I Antigen Processing and Presentation
Fang Zhou
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2009)
Myricetin Suppresses Invasion and Migration of Human Lung Adenocarcinoma A549 Cells: Possible Mediation by Blocking the ERK Signaling Pathway
Yuan-Wei Shih et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2009)
Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes
HyeonJoo Cheon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Share Paper
